AstraZeneca to acquire French drugmaker Amolyt Pharma for $1.05bn
UK-based AstraZeneca has agreed to acquire Amolyt Pharma, a France-based clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. Under the terms of the agreement,